2024
Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.
Pfeiffer P, Geller J, Ganoczy D, Jagusch J, Carty J, Festin F, Gilmer W, Martis B, Ranganathan M, Wiechers I, Hosanagar A. Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38206011, DOI: 10.4088/jcp.23m14984.Peer-Reviewed Original ResearchConceptsPHQ-9 scoresKetamine infusionClinical outcomesSymptom improvementInfusion frequencyPatient Health Questionnaire-9 scoreVeterans Health Administration electronic medical recordsBaseline PHQ-9 scoreShort-term clinical trialsAntidepressant medication trialsFirst ketamine infusionIntravenous ketamine treatmentMonths of infusionFrequency of infusionsMinority of patientsVA health systemWeeks of treatmentRoutine clinical practiceMajor depressive disorderNumber of infusionsElectronic medical recordsIntravenous ketamineKetamine treatmentFirst infusionMedication trials
2022
The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
McQuaid JR, Buelt A, Capaldi V, Fuller M, Issa F, Lang AE, Hoge C, Oslin DW, Sall J, Wiechers IR, Williams S. The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals Of Internal Medicine 2022, 175: 1440-1451. PMID: 36122380, DOI: 10.7326/m22-1603.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesMajor depressive disorderVeterans AffairsDepressive disorderPractice guidelinesDefense Clinical Practice GuidelineJoint clinical practice guidelineManagement of MDDTrustworthy clinical practice guidelinesUse of telemedicineMedicine's tenetsPharmacologic managementGuideline panelAlternative therapiesGRADE systemKey recommendationsPrior recommendationsClinical stakeholdersImportant new evidenceDisordersSelect recommendationsDepartmentGuidelinesManagementRecommendationsEffect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki S, Bjork J, Blow F, Brenner L, Chen P, Desai S, Dieperink E, Fears S, Fuller M, Goodman C, Graham D, Haas G, Hamner M, Helstrom A, Hurley R, Icardi M, Jurjus G, Kilbourne A, Kreyenbuhl J, Lache D, Lieske S, Lynch J, Meyer L, Montalvo C, Muralidhar S, Ostacher M, Paschall G, Pfeiffer P, Prieto S, Przygodzki R, Ranganathan M, Rodriguez-Suarez M, Roggenkamp H, Schichman S, Schneeweis J, Simonetti J, Steinhauer S, Suppes T, Umbert M, Vassy J, Voora D, Wiechers I, Wood A. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA 2022, 328: 151-161. PMID: 35819423, PMCID: PMC9277497, DOI: 10.1001/jama.2022.9805.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPatient Health Questionnaire-9Usual care groupUsual carePharmacogenomic testingDrug-gene interactionsRemission rateMedication selectionCare groupDepressive disorderVeterans Affairs Medical CenterActive substance use disorderCo-primary outcomesPrescription of medicationsBetter clinical outcomesProportion of prescriptionsRemission of symptomsSubstance use disordersEligible patientsWeek 24Effective antidepressantSingle antidepressantClinical outcomesInitial treatmentQuestionnaire-9